{
    "id": "dbpedia_1326_3",
    "rank": 23,
    "data": {
        "url": "https://diabetesjournals.org/care/article/31/Supplement_1/S12/24521/Standards-of-Medical-Care-in-Diabetes-2008",
        "read_more_link": "",
        "language": "en",
        "title": "Standards of Medical Care in Diabetes—2008",
        "top_image": "https://ada.silverchair-cdn.com/ada/content_public/journal/care/issue/31/supplement_1/3/m_diacare_31_suppl_1_cover.png?Expires=1786619142&Signature=g1q~DpGqDu4liYS19rCeued-gChxDJB73k9-8mWuNv7zxLIaScNGi7-Fah~dV6Hcd8fLGoSYP7Nyp7VwP1xYgJWxbZMgbqn7X1uPaORFEwxFL3VRD4Ee1yCSHe-hMRkScqxzpalWC62QnYYnYcY6gfrNbQWDXfIpEtbYheWzoogEbwRyVsvbhw-aUiGWjPeUC5qaRa8ttHjmrJOcTcOk2qh46GIsyDyiwAwZiS-v4AcwnISUUElVpGXNdnPVXK-zYWmN7DolFuVQXFxHd1JkYiRKgWzTBIt9LXTNrTZjQb56gdk-~vkSse1P1Wr1hu2uYtRWr~iaYZ4IqyFgnKP99A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
        "meta_img": "https://ada.silverchair-cdn.com/ada/content_public/journal/care/issue/31/supplement_1/3/m_diacare_31_suppl_1_cover.png?Expires=1786619142&Signature=g1q~DpGqDu4liYS19rCeued-gChxDJB73k9-8mWuNv7zxLIaScNGi7-Fah~dV6Hcd8fLGoSYP7Nyp7VwP1xYgJWxbZMgbqn7X1uPaORFEwxFL3VRD4Ee1yCSHe-hMRkScqxzpalWC62QnYYnYcY6gfrNbQWDXfIpEtbYheWzoogEbwRyVsvbhw-aUiGWjPeUC5qaRa8ttHjmrJOcTcOk2qh46GIsyDyiwAwZiS-v4AcwnISUUElVpGXNdnPVXK-zYWmN7DolFuVQXFxHd1JkYiRKgWzTBIt9LXTNrTZjQb56gdk-~vkSse1P1Wr1hu2uYtRWr~iaYZ4IqyFgnKP99A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
        "images": [
            "https://ada.silverchair-cdn.com/data/SiteBuilderAssetsOriginals/Live/Images/umbrella/logo-umbrella.svg",
            "https://ada.silverchair-cdn.com/data/SiteBuilderAssetsOriginals/Live/Images/umbrella/logo-umbrella.svg",
            "https://ada.silverchair-cdn.com/data/SiteBuilderAssets/Live/Images/care/care-header-164122153.svg",
            "https://ada.silverchair-cdn.com/ada/content_public/journal/care/issue/31/supplement_1/3/m_diacare_31_suppl_1_cover.png?Expires=1728106295&Signature=jH0HnsPQcS6exXc0i8V42X3hAG4hwNgOvwbzJEvqZxnfz4TcyGg8oCzkliT291n0O1i5bk4fvraSoIZ3zHVlx6iE4pfhavvGmepV7waC7SOFbxNgFhb6QYS03EX0ZKtLte0llP61MAMY2E7QB~oIKt3t3RwVjbZpcNZULARtRubb0DXiE27LKjHYo7CBGkuPJx1NPayinvoCQeP2OGEKL8LLp~II6AovGqXv9VLyPcNzFI9ZpyYrezMRZnqLc~H-jjHRwCpDVDkLCgxTc1cDqWEX8eET60L4kBAxVis~sPVFqiBv4pXjt6eeNW4OaJPuZehzWUCcb7Xo48CAQXHcig__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg",
            "https://ada.silverchair-cdn.com/data/SiteBuilderAssetsOriginals/Live/images/umbrella/logo-umbrella-footer.svg?versionId=4952"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "American Diabetes Association"
        ],
        "publish_date": "2008-01-01T00:00:00",
        "summary": "",
        "meta_description": "Diabetes is a chronic illness that requires continuing medical care and patient self-management education to prevent acute complications and to reduce the",
        "meta_lang": "en",
        "meta_favicon": "//ada.silverchair-cdn.com/data/SiteBuilderAssetsOriginals/Live/Images/umbrella/apple-touch-icon.png",
        "meta_site_name": "American Diabetes Association",
        "canonical_link": "https://diabetesjournals.org/care/article/31/Supplement_1/S12/24521/Standards-of-Medical-Care-in-Diabetes-2008",
        "text": "1.\n\nMedical Management of Type 1 Diabetes.\n\nAlexandria, VA, American Diabetes Association,\n\n2004\n\n2.\n\nMedical Management of Type 2 Diabetes.\n\nAlexandria, VA, American Diabetes Association,\n\n2004\n\n3.\n\nIntensive Diabetes Management.\n\nAlexandria, VA, American Diabetes Association,\n\n2003\n\n4.\n\nExpert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.\n\nDiabetes Care\n\n20\n\n:\n\n1183\n\n–1197,\n\n1997\n\n5.\n\nExpert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus.\n\nDiabetes Care\n\n26\n\n:\n\n3160\n\n–3167,\n\n2003\n\n6.\n\nDavidson MB, Schriger DL, Peters AL, Lorber B: Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria.\n\nJAMA\n\n281\n\n:\n\n1203\n\n–1210,\n\n1999\n\n7.\n\nNathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B: Impaired fasting glucose and impaired glucose tolerance: implications for care.\n\nDiabetes Care\n\n30\n\n:\n\n753\n\n–759,\n\n2007\n\n8.\n\nEngelgau MM, Narayan KM, Herman WH: Screening for type 2 diabetes.\n\nDiabetes Care\n\n23\n\n:\n\n1563\n\n–1580,\n\n2000\n\n9.\n\nGabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, Knowler WC: The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes.\n\nDiabetes Care\n\n23\n\n:\n\n1108\n\n–1112,\n\n2000\n\n10.\n\nKnowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.\n\nN Engl J Med\n\n346\n\n:\n\n393\n\n–403,\n\n2002\n\n11.\n\nTuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.\n\nN Engl J Med\n\n344\n\n:\n\n1343\n\n–1350,\n\n2001\n\n12.\n\nPan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.\n\nDiabetes Care\n\n20\n\n:\n\n537\n\n–544,\n\n1997\n\n13.\n\nBuchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.\n\nDiabetes\n\n51\n\n:\n\n2796\n\n–2803,\n\n2002\n\n14.\n\nChiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.\n\nLancet\n\n359\n\n:\n\n2072\n\n–2077,\n\n2002\n\n15.\n\nRamachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V: The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).\n\nDiabetologia\n\n49\n\n:\n\n289\n\n–297,\n\n2006\n\n16.\n\nGerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.\n\nLancet\n\n368\n\n:\n\n1096\n\n–1105,\n\n2006\n\n17.\n\nJohnson SL, Tabaei BP, Herman WH: The efficacy and cost of alternative strategies for systematic screening for type 2 diabetes in the U.S. population 45–74 years of age.\n\nDiabetes Care\n\n28\n\n:\n\n307\n\n–311,\n\n2005\n\n18.\n\nHarris R, Donahue K, Rathore SS, Frame P, Woolf SH, Lohr KN: Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force.\n\nAnn Intern Med\n\n138\n\n:\n\n215\n\n–229,\n\n2003\n\n19.\n\nUSPSTF: Screening for type 2 diabetes mellitus in adults: recommendations and rationale.\n\nAnn Intern Med\n\n138\n\n:\n\n212\n\n–214,\n\n2003\n\n20.\n\nDabelea D, Bell RA, D'Agostino RB, Jr, Imperatore G, Johansen JM, Linder B, Liu LL, Loots B, Marcovina S, Mayer-Davis EJ, Pettitt DJ, Waitzfelder B: Incidence of diabetes in youth in the United States.\n\nJAMA\n\n297\n\n:\n\n2716\n\n–2724,\n\n2007\n\n21.\n\nLiese AD, D'Agostino RB, Jr, Hamman RF, Kilgo PD, Lawrence JM, Liu LL, Loots B, Linder B, Marcovina S, Rodriguez B, Standiford D, Williams DE: The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study.\n\nPediatrics\n\n118\n\n:\n\n1510\n\n–1518,\n\n2006\n\n22.\n\nAmerican Diabetes Association: Type 2 diabetes in children and adolescents (Consensus Statement).\n\nDiabetes Care\n\n23\n\n:\n\n381\n\n–389,\n\n2000\n\n23.\n\nAmerican Diabetes Association: Gestational diabetes mellitus (Position Statement).\n\nDiabetes Care\n\n27(Suppl. 1)\n\n:\n\nS88\n\n–S90,\n\n2004\n\n24.\n\nKim C, Newton KM, Knopp RH: Gestational diabetes and the incidence of type 2 diabetes: a systematic review.\n\nDiabetes Care\n\n25\n\n:\n\n1862\n\n–1868,\n\n2002\n\n25.\n\nGerstein HC: Point: If it is important to prevent type 2 diabetes, it is important to consider all proven therapies within a comprehensive approach.\n\nDiabetes Care\n\n30\n\n:\n\n432\n\n–434,\n\n2007\n\n26.\n\nAmerican Diabetes Association: Consensus statement on self-monitoring of blood glucose.\n\nDiabetes Care\n\n10\n\n:\n\n95\n\n–99,\n\n1987\n\n27.\n\nAmerican Diabetes Association: Self-monitoring of blood glucose. American Diabetes Association.\n\nDiabetes Care\n\n17\n\n:\n\n81\n\n–86,\n\n1994\n\n28.\n\nWelschen LM, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman WA, Bouter LM: Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review.\n\nDiabetes Care\n\n28\n\n:\n\n1510\n\n–1517,\n\n2005\n\n29.\n\nSacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.\n\nClin Chem\n\n48\n\n:\n\n436\n\n–472,\n\n2002\n\n30.\n\nGarg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, Jovanovic L: Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial.\n\nDiabetes Care\n\n29\n\n:\n\n44\n\n–50,\n\n2006\n\n31.\n\nStratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.\n\nBMJ\n\n321\n\n:\n\n405\n\n–412,\n\n2000\n\n32.\n\nCagliero E, Levina EV, Nathan DM: Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients.\n\nDiabetes Care\n\n22\n\n:\n\n1785\n\n–1789,\n\n1999\n\n33.\n\nMiller CD, Barnes CS, Phillips LS, Ziemer DC, Gallina DL, Cook CB, Maryman SD, El Kebbi IM: Rapid A1c availability improves clinical decision-making in an urban primary care clinic.\n\nDiabetes Care\n\n26\n\n:\n\n1158\n\n–1163,\n\n2003\n\n34.\n\nRohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE: Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial.\n\nDiabetes Care\n\n25\n\n:\n\n275\n\n–278,\n\n2002\n\n35.\n\nDCCT: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group.\n\nN Engl J Med\n\n329\n\n:\n\n977\n\n–986,\n\n1993\n\n36.\n\nDCCT-EDIC: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.\n\nN Engl J Med\n\n342\n\n:\n\n381\n\n–389,\n\n2000\n\n37.\n\nMartin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, Stevens MJ, Feldman EL: Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion.\n\nDiabetes Care\n\n29\n\n:\n\n340\n\n–344,\n\n2006\n\n38.\n\nNathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.\n\nN Engl J Med\n\n353\n\n:\n\n2643\n\n–2653,\n\n2005\n\n39.\n\nOhkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.\n\nDiabetes Res Clin Pract\n\n28\n\n:\n\n103\n\n–117,\n\n1995\n\n40.\n\nUKPDS: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.\n\nLancet\n\n352\n\n:\n\n854\n\n–865,\n\n1998\n\n41.\n\nUKPDS: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.\n\nLancet\n\n352\n\n:\n\n837\n\n–853,\n\n1998\n\n42.\n\nKuusisto J, Mykkanen L, Pyorala K, Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects.\n\nDiabetes\n\n43\n\n:\n\n960\n\n–967,\n\n1994\n\n43.\n\nSelvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH: Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus.\n\nAnn Intern Med\n\n141\n\n:\n\n421\n\n–431,\n\n2004\n\n44.\n\nLawson ML, Gerstein HC, Tsui E, Zinman B: Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis.\n\nDiabetes Care\n\n22(Suppl. 2)\n\n:\n\nB35\n\n–B39,\n\n1999\n\n45.\n\nAmerican Diabetes Association: Postprandial blood glucose (Consensus Statement).\n\nDiabetes Care\n\n24\n\n:\n\n775\n\n–778,\n\n2001\n\n46.\n\nCeriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E: Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment.\n\nCirculation\n\n106\n\n:\n\n1211\n\n–1218,\n\n2002\n\n47.\n\nMetzger BE, Coustan DR: Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The Organizing Committee.\n\nDiabetes Care\n\n21(Suppl. 2)\n\n:\n\nB161\n\n–B167,\n\n1998\n\n48.\n\nDeWitt DE, Hirsch IB: Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review.\n\nJAMA\n\n289\n\n:\n\n2254\n\n–2264,\n\n2003\n\n49.\n\nRosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A: Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes.\n\nDiabetes Care\n\n28\n\n:\n\n950\n\n–955,\n\n2005\n\n50.\n\nMooradian AD, Bernbaum M, Albert SG: Narrative review: a rational approach to starting insulin therapy.\n\nAnn Intern Med\n\n145\n\n:\n\n125\n\n–134,\n\n2006\n\n51.\n\nNathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B: Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.\n\nDiabetes Care\n\n29\n\n:\n\n1963\n\n–1972,\n\n2006\n\n52.\n\nNissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.\n\nN Engl J Med\n\n356\n\n:\n\n2457\n\n–2471,\n\n2007\n\n53.\n\nSingh S, Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.\n\nJAMA\n\n298\n\n:\n\n1189\n\n–1195,\n\n2007\n\n54.\n\nAmerican Diabetes Association. Nutrition Recommendations and Interventions for Diabetes—\n\n2008\n\n.\n\nDiabetes Care\n\n31(Suppl. 1)\n\n:\n\nS61\n\n–S78,\n\n2008\n\n55.\n\nPastors JG, Warshaw H, Daly A, Franz M, Kulkarni K: The evidence for the effectiveness of medical nutrition therapy in diabetes management.\n\nDiabetes Care\n\n25\n\n:\n\n608\n\n–613,\n\n2002\n\n56.\n\nPastors JG, Franz MJ, Warshaw H, Daly A, Arnold MS: How effective is medical nutrition therapy in diabetes care?\n\nJ Am Diet Assoc\n\n103\n\n:\n\n827\n\n–831,\n\n2003\n\n57.\n\nYu-Poth S, Zhao G, Etherton T, Naglak M, Jonnalagadda S, Kris-Etherton PM: Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis.\n\nAm J Clin Nutr\n\n69\n\n:\n\n632\n\n–646,\n\n1999\n\n58.\n\nAppel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N: A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group.\n\nN Engl J Med\n\n336\n\n:\n\n1117\n\n–1124,\n\n1997\n\n59.\n\nNorris SL, Zhang X, Avenell A, Gregg E, Bowman B, Schmid CH, Lau J: Long-term effectiveness of weight-loss interventions in adults with pre-diabetes: a review.\n\nAm J Prev Med\n\n28\n\n:\n\n126\n\n–139,\n\n2005\n\n60.\n\nKlein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, Kulkarni K, Clark NG: Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition.\n\nDiabetes Care\n\n27\n\n:\n\n2067\n\n–2073,\n\n2004\n\n61.\n\nNorris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Kim C, Lau J: Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis.\n\nArch Intern Med\n\n164\n\n:\n\n1395\n\n–1404,\n\n2004\n\n62.\n\nWolf AM, Conaway MR, Crowther JQ, Hazen KY, Nadler L, Oneida B, Bovbjerg VE: Translating lifestyle intervention to practice in obese patients with type 2 diabetes: Improving Control with Activity and Nutrition (ICAN) study.\n\nDiabetes Care\n\n27\n\n:\n\n1570\n\n–1576,\n\n2004\n\n63.\n\nManning RM, Jung RT, Leese GP, Newton RW: The comparison of four weight reduction strategies aimed at overweight patients with diabetes mellitus: four-year follow-up.\n\nDiabet Med\n\n15\n\n:\n\n497\n\n–502,\n\n1998\n\n64.\n\nPi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, Curtis JM, Espeland MA, Foreyt JP, Graves K, Haffner SM, Harrison B, Hill JO, Horton ES, Jakicic J, Jeffery RW, Johnson KC, Kahn S, Kelley DE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montgomery B, Nathan DM, Patricio J, Peters A, Redmon JB, Reeves RS, Ryan DH, Safford M, Van Dorsten B, Wadden TA, Wagenknecht L, Wesche-Thobaben J, Wing RR, Yanovski SZ: Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial.\n\nDiabetes Care\n\n30\n\n:\n\n1374\n\n–1383,\n\n2007\n\n65.\n\nFoster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, Szapary PO, Rader DJ, Edman JS, Klein S: A randomized trial of a low-carbohydrate diet for obesity.\n\nN Engl J Med\n\n348\n\n:\n\n2082\n\n–2090,\n\n2003\n\n66.\n\nStern L, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, Williams M, Gracely EJ, Samaha FF: The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial.\n\nAnn Intern Med\n\n140\n\n:\n\n778\n\n–785,\n\n2004\n\n67.\n\nGardner C, Kiazand A, Alhassan S, Soowon K, Stafford R, Balise R, Kraemer H, and King A: Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women.\n\nJAMA\n\n297\n\n:\n\n969\n\n–977,\n\n2007\n\n68.\n\nNordmann AJ, Nordmann A, Briel M, Keller U, Yancy WS, Jr, Brehm BJ, Bucher HC: Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials.\n\nArch Intern Med\n\n166\n\n:\n\n285\n\n–293,\n\n2006\n\n69.\n\nInstitute of Medicine:\n\nDietary Reference Intakes: Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids.\n\nNational Academies Press, Washington, DC,\n\n2002\n\n70.\n\nFranz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, Holzmeister LA, Hoogwerf B, Mayer-Davis E, Mooradian AD, Purnell JQ, Wheeler M: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications.\n\nDiabetes Care\n\n25\n\n:\n\n148\n\n–198,\n\n2002\n\n71.\n\nPiette JD, Glasgow RE: Strategies for improving behavioral and health outcomes among people with diabetes: self-management education. In\n\nEvidence-Based Diabetes Care.\n\nGerstein HC, Hayes RB, Eds. BC Decker, Ontario, Canada,\n\n2000\n\n72.\n\nNorris SL, Engelgau MM, Narayan KM: Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials.\n\nDiabetes Care\n\n24\n\n:\n\n561\n\n–587,\n\n2001\n\n73.\n\nNorris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM: Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control.\n\nDiabetes Care\n\n25\n\n:\n\n1159\n\n–1171,\n\n2002\n\n74.\n\nGary TL, Genkinger JM, Guallar E, Peyrot M, Brancati FL: Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes.\n\nDiabetes Educ\n\n29\n\n:\n\n488\n\n–501,\n\n2003\n\n75.\n\nSteed L, Cooke D, Newman S: A systematic review of psychosocial outcomes following education, self-management and psychological interventions in diabetes mellitus.\n\nPatient Educ Couns\n\n51\n\n:\n\n5\n\n–15,\n\n2003\n\n76.\n\nEllis SE, Speroff T, Dittus RS, Brown A, Pichert JW, Elasy TA: Diabetes patient education: a meta-analysis and meta-regression.\n\nPatient Educ Couns\n\n52\n\n:\n\n97\n\n–105,\n\n2004\n\n77.\n\nWarsi A, Wang PS, LaValley MP, Avorn J, Solomon DH: Self-management education programs in chronic disease: a systematic review and methodological critique of the literature.\n\nArch Intern Med\n\n164\n\n:\n\n1641\n\n–1649,\n\n2004\n\n78.\n\nFunnell MM, Brown TL, Childs BP, Haas LB, Hosey GM, Jensen B, Maryniuk M, Peyrot M, Piette JD, Reader D, Siminerio LM, Weinger K, Weiss MA: National standards for diabetes self-management education.\n\nDiabetes Care\n\n30\n\n:\n\n1630\n\n–1637,\n\n2007\n\n79.\n\nMulcahy K, Maryniuk M, Peeples M, Peyrot M, Tomky D, Weaver T, Yarborough P: Diabetes self-management education core outcomes measures.\n\nDiabetes Educ\n\n29\n\n:\n\n768-84\n\n:787,\n\n2003\n\n80.\n\nBarker JM, Goehrig SH, Barriga K, Hoffman M, Slover R, Eisenbarth GS, Norris JM, Klingensmith GJ, Rewers M: Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up.\n\nDiabetes Care\n\n27\n\n:\n\n1399\n\n–1404,\n\n2004\n\n81.\n\nRickheim PL, Weaver TW, Flader JL, Kendall DM: Assessment of group versus individual diabetes education: a randomized study.\n\nDiabetes Care\n\n25\n\n:\n\n269\n\n–274,\n\n2002\n\n82.\n\nTrento M, Passera P, Borgo E, Tomalino M, Bajardi M, Cavallo F, Porta M: A 5-year randomized controlled study of learning, problem solving ability, and quality of life modifications in people with type 2 diabetes managed by group care.\n\nDiabetes Care\n\n27\n\n:\n\n670\n\n–675,\n\n2004\n\n83.\n\nNorris SL, Chowdhury FM, Van Le K, Horsley T, Brownstein JN, Zhang X, Jack L, Jr, Satterfield DW: Effectiveness of community health workers in the care of persons with diabetes.\n\nDiabet Med\n\n23\n\n:\n\n544\n\n–556,\n\n2006\n\n84.\n\nSigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C: Physical activity/exercise and type 2 diabetes.\n\nDiabetes Care\n\n27\n\n:\n\n2518\n\n–2539,\n\n2004\n\n85.\n\nWasserman DH, Zinman B: Exercise in individuals with IDDM.\n\nDiabetes Care\n\n17\n\n:\n\n924\n\n–937,\n\n1994\n\n86.\n\nBoulé NG, Haddad E, Kenny GP, Wells GA, Sigal RJ: Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials.\n\nJAMA\n\n286\n\n:\n\n1218\n\n–1227,\n\n2001\n\n87.\n\nBoulé NG, Kenny GP, Haddad E, Wells GA, Sigal RJ: Meta-analysis of the effect of structured exercise training on cardiorespiratory fitness in type 2 diabetes mellitus.\n\nDiabetologia\n\n46\n\n:\n\n1071\n\n–1081,\n\n2003\n\n88.\n\nUS Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion:\n\nPhysical Activity and Health: A Report of the Surgeon General.\n\nAtlanta, GA, Centers for Disease Control and Prevention, 1996\n\n89.\n\nIvy JL: Role of exercise training in the prevention and treatment of insulin resistance and non-insulin-dependent diabetes mellitus.\n\nSports Med\n\n24\n\n:\n\n321\n\n–336,\n\n1997\n\n90.\n\nDunstan DW, Daly RM, Owen N, Jolley D, de Court, Shaw J, Zimmet P: High-intensity resistance training improves glycemic control in older patients with type 2 diabetes.\n\nDiabetes Care\n\n25\n\n:\n\n1729\n\n–1736,\n\n2002\n\n91.\n\nCastaneda C, Layne JE, Munoz-Orians L, Gordon PL, Walsmith J, Foldvari M, Roubenoff R, Tucker KL, Nelson ME: A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes.\n\nDiabetes Care\n\n25\n\n:\n\n2335\n\n–2341,\n\n2002\n\n92.\n\nSigal RJ, Kenny GP, Boule NG, Wells GA, Prud'homme D, Fortier M, Reid RD, Tulloch H, Coyle D, Phillips P, Jennings A, Jaffey J: Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial.\n\nAnn Intern Med\n\n147\n\n:\n\n357\n\n–369,\n\n2007\n\n93.\n\nBax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ: Screening for coronary artery disease in patients with diabetes.\n\nDiabetes Care\n\n30\n\n:\n\n2729\n\n–2736,\n\n2007\n\n94.\n\nBerger M, Berchtold P, Cuppers HJ, Drost H, Kley HK, Muller WA, Wiegelmann W, Zimmerman-Telschow H, Gries FA, Kruskemper HL, Zimmermann H: Metabolic and hormonal effects of muscular exercise in juvenile type diabetics.\n\nDiabetologia\n\n13\n\n:\n\n355\n\n–365,\n\n1977\n\n95.\n\nAmerican Diabetes Association: Physical activity/exercise and diabetes (Position Statement).\n\nDiabetes Care\n\n27(Suppl. 1)\n\n:\n\nS58\n\n–S62,\n\n2004\n\n96.\n\nBerger M: Adjustment of insulin and oral agent therapy. In\n\nHandbook of Exercise in Diabetes.\n\n2nd ed. Ruderman N, Devlin JT, Krisska A, Eds. Alexandria, VA, American Diabetes Association,\n\n2002\n\n, p.\n\n365\n\n–376\n\n97.\n\nAiello LP, Wong J, Cavallerano J, Bursell SE, Aiello LM: Retinopathy. In Handbook of Exercise in Diabetes. 2nd ed. Ruderman N, Devlin JT, Kriska A, Eds. Alexandria, VA, American Diabetes Association,\n\n2002\n\n, p.\n\n401\n\n–413\n\n98.\n\nVinik A, Erbas T: Neuropathy. In\n\nHandbook of Exercise in Diabetes.\n\n2nd ed. Ruderman N, Devlin JT, Kriska A, Eds. Alexnadria, VA, American Diabetes Association,\n\n2002\n\n, p.\n\n463\n\n–496\n\n99.\n\nLevin ME: The diabetic foot. In Handbook of Exercise in Diabetes. Ruderman N, Devlin JT, Kriska A, Eds. Alexandria, VA, American Diabetes Association,\n\n2002\n\n, p.\n\n385\n\n–399\n\n100.\n\nWackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Heller GV, Filipchuk N, Engel S, Ratner RE, Iskandrian AE: Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study.\n\nDiabetes Care\n\n27\n\n:\n\n1954\n\n–1961,\n\n2004\n\n101.\n\nValensi P, Sachs RN, Harfouche B, Lormeau B, Paries J, Cosson E, Paycha F, Leutenegger M, Attali JR: Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia.\n\nDiabetes Care\n\n24\n\n:\n\n339\n\n–343,\n\n2001\n\n102.\n\nMogensen CE: Nephropathy. In\n\nHandbook of Exercise in Diabetes.\n\n2nd ed. Ruderman N, Devlin JT, Kriska A, Eds. Alexandria, VA, American Diabetes Association,\n\n2002\n\n, p.\n\n433\n\n–449\n\n103.\n\nAnderson RJ, Grigsby AB, Freedland KE, de Groot M, McGill JB, Clouse RE, Lustman PJ: Anxiety and poor glycemic control: a meta-analytic review of the literature.\n\nInt J Psychiatry Med\n\n32\n\n:\n\n235\n\n–247,\n\n2002\n\n104.\n\nJacobson AM: Depression and diabetes.\n\nDiabetes Care\n\n16\n\n:\n\n1621\n\n–1623,\n\n1993\n\n105.\n\nRubin RR, Peyrot M: Psychosocial problems and interventions in diabetes: a review of the literature.\n\nDiabetes Care\n\n15\n\n:\n\n1640\n\n–1657,\n\n1992\n\n106.\n\nSurwit RS, Schneider MS, Feinglos MN: Stress and diabetes mellitus.\n\nDiabetes Care\n\n15\n\n:\n\n1413\n\n–1422,\n\n1992\n\n107.\n\nYoung-Hyman D: Psycosocial factors affecting adherence, quality of life, and well-being: helping patients cope. In\n\nMedical Management of Type 1 Diabetes.\n\n4th ed. Bode B, Ed. Alexandria, VA, American Diabetes Association,\n\n2004\n\n, p.\n\n162\n\n–182\n\n108.\n\nDelahanty LM, Grant RW, Wittenberg E, Bosch JL, Wexler DJ, Cagliero E, Meigs JB: Association of diabetes-related emotional distress with diabetes treatment in primary care patients with type 2 diabetes.\n\nDiabet Med\n\n24\n\n:\n\n48\n\n–54,\n\n2007\n\n109.\n\nAnderson BJ, Auslander WF, Jung KC, Miller JP, Santiago JV: Assessing family sharing of diabetes responsibilities.\n\nJ Pediatr Psychol\n\n15\n\n:\n\n477\n\n–492,\n\n1990\n\n110.\n\nMcCulloch DK, Glasgow RE, Hampson SE, Wagner E: A systematic approach to diabetes management in the post-DCCT era.\n\nDiabetes Care\n\n17\n\n:\n\n765\n\n–769,\n\n1994\n\n111.\n\nRubin RR, Peyrot M: Psychological issues and treatments for people with diabetes.\n\nJ Clin Psychol\n\n57\n\n:\n\n457\n\n–478,\n\n2001\n\n112.\n\nPeyrot M, Rubin RR: Behavioral and psychosocial interventions in diabetes: a conceptual review.\n\nDiabetes Care\n\n30\n\n:\n\n2433\n\n–2440,\n\n2007\n\n113.\n\nLustman PJ, Griffith LS, Clouse RE, Cryer PE: Psychiatric illness in diabetes mellitus: relationship to symptoms and glucose control.\n\nJ Nerv Ment Dis\n\n174\n\n:\n\n736\n\n–742,\n\n1986\n\n114.\n\nMarcus MD, Wing RR: Eating disorders and diabetes. In\n\nNeuropsychological and Behavioral Aspects of Diabetes.\n\nHolmes CS, Ed. New York, Springer-Verlag,\n\n1990\n\n, p.\n\n102\n\n–121\n\n115.\n\nPeyrot M, Rubin RR: Behavioral and psychosocial interventions in diabetes: a conceptual review.\n\nDiabetes Care\n\n30\n\n:\n\n2433\n\n–2440,\n\n2007\n\n116.\n\nAmerican Diabetes Association: Hyperglycemic crises in diabetes.\n\nDiabetes Care\n\n27(Suppl. 1)\n\n:\n\nS94\n\n–S102,\n\n2004\n\n117.\n\nCryer PE: Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.\n\nDiabetologia\n\n45\n\n:\n\n937\n\n–948,\n\n2002\n\n118.\n\nGannon MC, Nuttall FQ: Protein and Diabetes. In\n\nAmerican Diabetes Association Guide to Medical Nutrition Therapy for Diabetes.\n\nFranz MJ, Bantle JP, Eds. Alexandria, VA, American Diabetes Association,\n\n1999\n\n, p.\n\n107\n\n–125\n\n119.\n\nCryer PE: Diverse causes of hypoglycemia-associated autonomic failure in diabetes.\n\nN Engl J Med\n\n350\n\n:\n\n2272\n\n–2279,\n\n2004\n\n120.\n\nCryer PE, Davis SN, Shamoon H: Hypoglycemia in diabetes.\n\nDiabetes Care\n\n26\n\n:\n\n1902\n\n–1912,\n\n2003\n\n121.\n\nSmith SA, Poland GA: Use of influenza and pneumococcal vaccines in people with diabetes.\n\nDiabetes Care\n\n23\n\n:\n\n95\n\n–108,\n\n2000\n\n122.\n\nColquhoun AJ, Nicholson KG, Botha JL, Raymond NT: Effectiveness of influenza vaccine in reducing hospital admissions in people with diabetes.\n\nEpidemiol Infect\n\n119\n\n:\n\n335\n\n–341,\n\n1997\n\n123.\n\nBridges CB, Fukuda K, Uyeki TM, Cox NJ, Singleton JA: Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP).\n\nMMWR Recomm Rep\n\n51\n\n:\n\n1\n\n–31,\n\n2002\n\n124.\n\nAmerican Diabetes Association: Influenza and pneumococcal immunization in diabetes (Position Statement).\n\nDiabetes Care\n\n27(Suppl. 1)\n\n:\n\nS111\n\n–S113,\n\n2004\n\n125.\n\nArauz-Pacheco C, Parrott MA, Raskin P: The treatment of hypertension in adult patients with diabetes.\n\nDiabetes Care\n\n25\n\n:\n\n134\n\n–147,\n\n2002\n\n126.\n\nHaffner SM: Management of dyslipidemia in adults with diabetes.\n\nDiabetes Care\n\n21\n\n:\n\n160\n\n–178,\n\n1998\n\n127.\n\nColwell JA: Aspirin therapy in diabetes.\n\nDiabetes Care\n\n20\n\n:\n\n1767\n\n–1771,\n\n1997\n\n128.\n\nHaire-Joshu D, Glasgow RE, Tibbs TL: Smoking and diabetes.\n\nDiabetes Care\n\n22\n\n:\n\n1887\n\n–1898,\n\n1999\n\n129.\n\nBuse JB, Ginsberg HN, Barkis GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone N: J Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.\n\nDiabetes Care\n\n30\n\n:\n\n162\n\n–172,\n\n2007\n\n130.\n\nChobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, Jones DW, Materson BJ, Oparil S, Wright JT, Jr, Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.\n\nJAMA\n\n289\n\n:\n\n2560\n\n–2572,\n\n2003\n\n131.\n\nBobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, Menard J, Mallion JM: Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients.\n\nJAMA\n\n291\n\n:\n\n1342\n\n–1349,\n\n2004\n\n132.\n\nSega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, Mancia G: Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study.\n\nCirculation\n\n111\n\n:\n\n1777\n\n–1783,\n\n2005\n\n133.\n\nUKPDS: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.\n\nBMJ\n\n317\n\n:\n\n703\n\n–713,\n\n1998\n\n134.\n\nHansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.\n\nLancet\n\n351\n\n:\n\n1755\n\n–1762,\n\n1998\n\n135.\n\nAdler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.\n\nBMJ\n\n321\n\n:\n\n412\n\n–419,\n\n2000\n\n136.\n\nLewington S, Clarke R, Qizilbash N, Peto R, Collins R: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.\n\nLancet\n\n360\n\n:\n\n1903\n\n–1913,\n\n2002\n\n137.\n\nStamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.\n\nDiabetes Care\n\n16\n\n:\n\n434\n\n–444,\n\n1993\n\n138.\n\nSacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER, III, Simons-Morton DG, Karanja N, Lin PH: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group.\n\nN Engl J Med\n\n344\n\n:\n\n3\n\n–10,\n\n2001\n\n139.\n\nTatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F: Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM.\n\nDiabetes Care\n\n21\n\n:\n\n597\n\n–603,\n\n1998\n\n140.\n\nEstacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.\n\nN Engl J Med\n\n338\n\n:\n\n645\n\n–652,\n\n1998\n\n141.\n\nSchrier RW, Estacio RO, Mehler PS, Hiatt WR: Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial.\n\nNat Clin Pract Nephrol\n\n3\n\n:\n\n428\n\n–438,\n\n2007\n\n142.\n\nALLHAT: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).\n\nJAMA\n\n288\n\n:\n\n2981\n\n–2997,\n\n2002\n\n143.\n\nPsaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS: Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.\n\nJAMA\n\n289\n\n:\n\n2534\n\n–2544,\n\n2003\n\n144.\n\nHOPE: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.\n\nLancet\n\n355\n\n:\n\n253\n\n–259,\n\n2000\n\n145.\n\nPfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.\n\nLancet\n\n362\n\n:\n\n759\n\n–766,\n\n2003\n\n146.\n\nGranger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.\n\nLancet\n\n362\n\n:\n\n772\n\n–776,\n\n2003\n\n147.\n\nMcMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.\n\nLancet\n\n362\n\n:\n\n767\n\n–771,\n\n2003\n\n148.\n\nLindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.\n\nLancet\n\n359\n\n:\n\n1004\n\n–1010,\n\n2002\n\n149.\n\nBerl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ: Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.\n\nAnn Intern Med\n\n138\n\n:\n\n542\n\n–549,\n\n2003\n\n150.\n\nLaffel LM, McGill JB, Gans DJ: The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group.\n\nAm J Med\n\n99\n\n:\n\n497\n\n–504,\n\n1995\n\n151.\n\nBakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J: Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.\n\nAm J Kidney Dis\n\n36\n\n:\n\n646\n\n–661,\n\n2000\n\n152.\n\nPsaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD: Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis.\n\nJAMA\n\n277\n\n:\n\n739\n\n–745,\n\n1997\n\n153.\n\nSibai BM: Treatment of hypertension in pregnant women.\n\nN Engl J Med\n\n335\n\n:\n\n257\n\n–265,\n\n1996\n\n154.\n\nBaigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.\n\nLancet\n\n366\n\n:\n\n1267\n\n–1278,\n\n2005\n\n155.\n\nPyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).\n\nDiabetes Care\n\n20\n\n:\n\n614\n\n–620,\n\n1997\n\n156.\n\nHeart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.\n\nLancet\n\n361\n\n:\n\n2005\n\n–2016,\n\n2003\n\n157.\n\nGoldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.\n\nCirculation\n\n98\n\n:\n\n2513\n\n–2519,\n\n1998\n\n158.\n\nShepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D: Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.\n\nDiabetes Care\n\n29\n\n:\n\n1220\n\n–1226,\n\n2006\n\n159.\n\nSever PS, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J: Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial–lipid-lowering arm (ASCOT-LLA).\n\nDiabetes Care\n\n28\n\n:\n\n1151\n\n–1157,\n\n2005\n\n160.\n\nKnopp RH, d'Emden M, Smilde JG, Pocock SJ: Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).\n\nDiabetes Care\n\n29\n\n:\n\n1478\n\n–1485,\n\n2006\n\n161.\n\nColhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.\n\nLancet\n\n364\n\n:\n\n685\n\n–696,\n\n2004\n\n162.\n\nSingh IM, Shishehbor MH, Ansell BJ: High-density lipoprotein as a therapeutic target: a systematic review.\n\nJAMA\n\n298\n\n:\n\n786\n\n–798,\n\n2007\n\n163.\n\nCanner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W: Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.\n\nJ Am Coll Cardiol\n\n8\n\n:\n\n1245\n\n–1255,\n\n1986\n\n164.\n\nRubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.\n\nN Engl J Med\n\n341\n\n:\n\n410\n\n–418,\n\n1999\n\n165.\n\nFrick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease.\n\nN Engl J Med\n\n317\n\n:\n\n1237\n\n–1245,\n\n1987\n\n166.\n\nKeech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.\n\nLancet\n\n366\n\n:\n\n1849\n\n–1861,\n\n2005\n\n167.\n\nNCEP: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).\n\nJAMA\n\n285\n\n:\n\n2486\n\n–2497,\n\n2001\n\n168.\n\nHayward RA, Hofer TP, Vijan S: Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem.\n\nAnn Intern Med\n\n145\n\n:\n\n520\n\n–530,\n\n2006\n\n169.\n\nCannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Intensive versus moderate lipid lowering with statins after acute coronary syndromes.\n\nN Engl J Med\n\n350\n\n:\n\n1495\n\n–1504,\n\n2004\n\n170.\n\nde Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.\n\nJAMA\n\n292\n\n:\n\n1307\n\n–1316,\n\n2004\n\n171.\n\nNissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.\n\nJAMA\n\n291\n\n:\n\n1071\n\n–1080,\n\n2004\n\n172.\n\nGrundy SM, Cleeman JI, Merz CN, Brewer HB, Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Jr, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.\n\nCirculation\n\n110\n\n:\n\n227\n\n–239,\n\n2004\n\n173.\n\nElam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, Kostis JB, Sheps DS, Brinton EA: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial.\n\nJAMA\n\n284\n\n:\n\n1263\n\n–1270,\n\n2000\n\n174.\n\nGrundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP: Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.\n\nArch Intern Med\n\n162\n\n:\n\n1568\n\n–1576,\n\n2002\n\n175.\n\nJones PH, Davidson MH: Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.\n\nAm J Cardiol\n\n95\n\n:\n\n120\n\n–122,\n\n2005\n\n176.\n\nAmerican Diabetes Association: Aspirin therapy in diabetes (Position Statement).\n\nDiabetes Care\n\n27(Suppl. 1)\n\n:\n\nS72\n\n–S73,\n\n2004\n\n177.\n\nHayden M, Pignone M, Phillips C, Mulrow C: Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force.\n\nAnn Intern Med\n\n136\n\n:\n\n161\n\n–172,\n\n2002\n\n178.\n\nUSPSTF: Aspirin for the primary prevention of cardiovascular events: recommendation and rationale.\n\nAnn Intern Med\n\n136\n\n:\n\n157\n\n–160,\n\n2002\n\n179.\n\nAntithrombotic Trialists Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.\n\nBMJ\n\n324\n\n:\n\n71\n\n–86,\n\n2002\n\n180.\n\nSmith SC, Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute.\n\nCirculation\n\n113\n\n:\n\n2363\n\n–2372,\n\n2006\n\n181.\n\nCampbell CL, Smyth S, Montalescot G, Steinhubl SR: Aspirin dose for the prevention of cardiovascular disease: a systematic review.\n\nJAMA\n\n297\n\n:\n\n2018\n\n–2024,\n\n2007\n\n182.\n\nSacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A: Primary Prevention of Cardiovascular Events With Low-Dose Aspirin and Vitamin E in Type 2 Diabetic Patients: Results of the Primary Prevention Project (PPP) trial.\n\nDiabetes Care\n\n26\n\n:\n\n3264\n\n–3272,\n\n2003\n\n183.\n\nBhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ: Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus.\n\nAm J Cardiol\n\n90\n\n:\n\n625\n\n–628,\n\n2002\n\n184.\n\nAmerican Diabetes Asociation: Smoking and diabetes (Position Statement).\n\nDiabetes Care\n\n27(Suppl. 1)\n\n:\n\nS74\n\n–S75,\n\n2004\n\n185.\n\nUS Preventive Services Task Force:\n\nCounseling to Prevent Tobacco Use and Tobacco-Related Diseases: Recommendation Statement.\n\nAgency for Healthcare Research and Quality, Rockville, MD,\n\n2003\n\n186.\n\nRanney L, Melvin C, Lux L, McClain E, Lohr KN: Systematic review: smoking cessation intervention strategies for adults and adults in special populations.\n\nAnn Intern Med\n\n145\n\n:\n\n845\n\n–856,\n\n2006\n\n187.\n\nAmerican Diabetes Asociation: Consensus development conference on the diagnosis of coronary heart disease in people with diabetes: 10–11 February 1998, Miami, Florida. American Diabetes Association.\n\nDiabetes Care\n\n21\n\n:\n\n1551\n\n–1559,\n\n1998\n\n188.\n\nScognamiglio R, Negut C, Ramondo A, Tiengo A, Avogaro A: Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus.\n\nJ Am Coll Cardiol\n\n47\n\n:\n\n65\n\n–71,\n\n2006\n\n189.\n\nBoden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS: Optimal medical therapy with or without PCI for stable coronary disease.\n\nN Engl J Med\n\n356\n\n:\n\n1503\n\n–1516,\n\n2007\n\n190.\n\nWackers FJ, Chyun DA, Young LH, Heller GV, Iskandrian AE, Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE: Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes mellitus in the DIAD Study.\n\nDiabetes Care\n\n2007\n\n191.\n\nGarg JP, Bakris GL: Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease.\n\nVasc Med\n\n7\n\n:\n\n35\n\n–43,\n\n2002\n\n192.\n\nKlausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, Appleyard M, Jensen JS: Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes.\n\nCirculation\n\n110\n\n:\n\n32\n\n–35,\n\n2004\n\n193.\n\nGall MA, Hougaard P, Borch-Johnsen K, Parving HH: Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study.\n\nBMJ\n\n314\n\n:\n\n783\n\n–788,\n\n1997\n\n194.\n\nRavid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study.\n\nArch Intern Med\n\n156\n\n:\n\n286\n\n–289,\n\n1996\n\n195.\n\nReichard P, Nilsson BY, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus.\n\nN Engl J Med\n\n329\n\n:\n\n304\n\n–309,\n\n1993\n\n196.\n\nDCCT: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group.\n\nKidney Int\n\n47\n\n:\n\n1703\n\n–1720,\n\n1995\n\n197.\n\nLewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.\n\nN Engl J Med\n\n329\n\n:\n\n1456\n\n–1462,\n\n1993\n\n198.\n\nRemuzzi G, Macia M, Ruggenenti P: Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study.\n\nJ Am Soc Nephrol\n\n17\n\n:\n\nS90\n\n–S97,\n\n2006\n\n199.\n\nLewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.\n\nN Engl J Med\n\n345\n\n:\n\n851\n\n–860,\n\n2001\n\n200.\n\nBrenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.\n\nN Engl J Med\n\n345\n\n:\n\n861\n\n–869,\n\n2001\n\n201.\n\nParving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.\n\nN Engl J Med\n\n345\n\n:\n\n870\n\n–878,\n\n2001\n\n202.\n\nPepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril study (INVEST): a randomized controlled trial.\n\nJAMA\n\n290\n\n:\n\n2805\n\n–2816,\n\n2003\n\n203.\n\nBakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, Agarwal R, Catanzaro D: ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.\n\nKidney Int\n\n58\n\n:\n\n2084\n\n–2092,\n\n2000\n\n204.\n\nPijls LT, de Vries H, Donker AJ, van Eijk JT: The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: a randomized trial.\n\nNephrol Dial Transplant\n\n14\n\n:\n\n1445\n\n–1453,\n\n1999\n\n205.\n\nPedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH: The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis.\n\nAnn Intern Med\n\n124\n\n:\n\n627\n\n–632,\n\n1996\n\n206.\n\nHansen HP, Tauber-Lassen E, Jensen BR, Parving HH: Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy.\n\nKidney Int\n\n62\n\n:\n\n220\n\n–228,\n\n2002\n\n207.\n\nKasiske BL, Lakatua JD, Ma JZ, Louis TA: A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function.\n\nAm J Kidney Dis\n\n31\n\n:\n\n954\n\n–961,\n\n1998\n\n208.\n\nEknoyan G, Hostetter T, Bakris GL, Hebert L, Levey AS, Parving HH, Steffes MW, Toto R: Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK).\n\nAm J Kidney Dis\n\n42\n\n:\n\n617\n\n–622,\n\n2003\n\n209.\n\nLevey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.\n\nAnn Intern Med\n\n139\n\n:\n\n137\n\n–147,\n\n2003\n\n210.\n\nKramer H, Molitch ME: Screening for kidney disease in adults with diabetes.\n\nDiabetes Care\n\n28\n\n:\n\n1813\n\n–1816,\n\n2005\n\n211.\n\nKramer HJ, Nguyen QD, Curhan G, Hsu CY: Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus.\n\nJAMA\n\n289\n\n:\n\n3273\n\n–3277,\n\n2003\n\n212.\n\nTsalamandris C, Allen TJ, Gilbert RE, Sinha A, Panagiotopoulos S, Cooper ME, Jerums G: Progressive decline in renal function in diabetic patients with and without albuminuria.\n\nDiabetes\n\n43\n\n:\n\n649\n\n–655,\n\n1994\n\n213.\n\nLevey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.\n\nAnn Intern Med\n\n130\n\n:\n\n461\n\n–470,\n\n1999\n\n214.\n\nLevinsky NG: Specialist evaluation in chronic kidney disease: too little, too late.\n\nAnn Intern Med\n\n137\n\n:\n\n542\n\n–543,\n\n2002\n\n215.\n\nAmerican Diabetes Association: Nephropathy in diabetes (Position Statement).\n\nDiabetes Care\n\n27(Suppl. 1)\n\n:\n\nS79\n\n–S83,\n\n2004\n\n216.\n\nKlein R: Hyperglycemia and microvascular and macrovascular disease in diabetes.\n\nDiabetes Care\n\n18\n\n:\n\n258\n\n–268,\n\n1995\n\n217.\n\nEstacio RO, McFarling E, Biggerstaff S, Jeffers BW, Johnson D, Schrier RW: Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM.\n\nAm J Kidney Dis\n\n31\n\n:\n\n947\n\n–953,\n\n1998\n\n218.\n\nLeske MC, Wu SY, Hennis A, Hyman L, Nemesure B, Yang L, Schachat AP: Hyperglycemia, blood pressure, and the 9-year incidence of diabetic retinopathy: the Barbados Eye Studies.\n\nOphthalmology\n\n112\n\n:\n\n799\n\n–805,\n\n2005\n\n219.\n\nFong DS, Aiello LP, Ferris FL, III, Klein R: Diabetic retinopathy.\n\nDiabetes Care\n\n27\n\n:\n\n2540\n\n–2553,\n\n2004\n\n220.\n\nDCCT: Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group.\n\nDiabetes Care\n\n23\n\n:\n\n1084\n\n–1091,\n\n2000\n\n221.\n\nThe Diabetic Retinopathy Study (DRS) Research Group. Preliminary report on the effects of photocoagulation therapy: DRS Report #1.\n\nAm J Ophthalmol\n\n81\n\n:\n\n383\n\n–396,\n\n1976\n\n222.\n\nETDRS: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.\n\nArch Ophthalmol\n\n103\n\n:\n\n1796\n\n–1806,\n\n1985\n\n223.\n\nKlein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years.\n\nArch Ophthalmol\n\n102\n\n:\n\n520\n\n–526,\n\n1984\n\n224.\n\nHarris MI, Klein R, Welborn TA, Knuiman MW: Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis.\n\nDiabetes Care\n\n15\n\n:\n\n815\n\n–819,\n\n1992\n\n225.\n\nVijan S, Hofer TP, Hayward RA: Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus.\n\nJAMA\n\n283\n\n:\n\n889\n\n–896,\n\n2000\n\n226.\n\nKlein R: Screening interval for retinopathy in type 2 diabetes.\n\nLancet\n\n361\n\n:\n\n190\n\n–191,\n\n2003\n\n227.\n\nYounis N, Broadbent DM, Vora JP, Harding SP: Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study.\n\nLancet\n\n361\n\n:\n\n195\n\n–200,\n\n2003\n\n228.\n\nAhmed J, Ward TP, Bursell SE, Aiello LM, Cavallerano JD, Vigersky RA: The sensitivity and specificity of nonmydriatic digital stereoscopic retinal imaging in detecting diabetic retinopathy.\n\nDiabetes Care\n\n29\n\n:\n\n2205\n\n–2209,\n\n2006\n\n229.\n\nAmerican Diabetes Association: Retinopathy in diabetes.\n\nDiabetes Care\n\n27(Suppl. 1)\n\n:\n\nS84\n\n–S87,\n\n2004\n\n230.\n\nCiulla TA, Amador AG, Zinman B: Diabetic Retinopathy and Diabetic Macular Edema: Pathophysiology, screening, and novel therapies.\n\nDiabetes Care\n\n26\n\n:\n\n2653\n\n–2664,\n\n2003\n\n231.\n\nBoulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D: Diabetic neuropathies: a statement by the American Diabetes Association.\n\nDiabetes Care\n\n28\n\n:\n\n956\n\n–962,\n\n2005\n\n232.\n\nVinik AI, Maser RE, Mitchell BD, Freeman R: Diabetic autonomic neuropathy.\n\nDiabetes Care\n\n26\n\n:\n\n1553\n\n–1579,\n\n2003\n\n233.\n\nAmerican Diabetes Association: Peripheral Arterial Disease in People With Diabetes (Consensus Statement).\n\nDiabetes Care\n\n26\n\n:\n\n3333\n\n–3341,\n\n2003\n\n234.\n\nMayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM: Preventive foot care in people with diabetes.\n\nDiabetes Care\n\n21\n\n:\n\n2161\n\n–2177,\n\n1998\n\n235.\n\nAmerican Diabetes Association: Preventive foot care in diabetes (Position Statement).\n\nDiabetes Care\n\n27(Suppl. 1)\n\n:\n\nS63\n\n–S64,\n\n2004\n\n236.\n\nAmerican Diabetes Association: Consensus Development Conference on Diabetic Foot Wound Care, 7–8 April 1999, Boston, Massachusetts. American Diabetes Association.\n\nDiabetes Care\n\n22\n\n:\n\n1354\n\n–1360,\n\n1999\n\n237.\n\nSilverstein J, Klingensmith G, Copeland KC, Plotnick L, Kaufman F, Laffel L, Deeb LC, Grey M, Anderson BJ, Holzmeister LA, Clark N, American Diabetes Association: Care of children and adolescents with type 1 diabetes mellitus: a statement of the American Diabetes Association.\n\nDiabetes Care\n\n28\n\n:\n\n186\n\n–212,\n\n2005\n\n238.\n\nNortham EA, Anderson PJ, Werther GA, Warne GL, Adler RG, Andrewes D: Neuropsychological complications of IDDM in children 2 years after disease onset.\n\nDiabetes Care\n\n21\n\n:\n\n379\n\n–384,\n\n1998\n\n239.\n\nRovet J, Alvarez M: Attentional functioning in children and adolescents with IDDM.\n\nDiabetes Care\n\n20\n\n:\n\n803\n\n–810,\n\n1997\n\n240.\n\nBjorgaas M, Gimse R, Vik T, Sand T: Cognitive function in type 1 diabetic children with and without episodes of severe hypoglycaemia.\n\nActa Paediatr\n\n86\n\n:\n\n148\n\n–153,\n\n1997\n\n241.\n\nDoyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV: A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine.\n\nDiabetes Care\n\n27\n\n:\n\n1554\n\n–1558,\n\n2004\n\n242.\n\nNimri R, Weintrob N, Benzaquen H, Ofan R, Fayman G, Phillip M: Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study.\n\nPediatrics\n\n117\n\n:\n\n2126\n\n–2131,\n\n2006\n\n243.\n\nKrantz JS, Mack WJ, Hodis HN, Liu CR, Liu CH, Kaufman FR: Early onset of subclinical atherosclerosis in young persons with type 1 diabetes.\n\nJ Pediatr\n\n145\n\n:\n\n452\n\n–457,\n\n2004\n\n244.\n\nJarvisalo MJ, Putto-Laurila A, Jartti L, Lehtimaki T, Solakivi T, Ronnemaa T, Raitakari OT: Carotid artery intima-media thickness in children with type 1 diabetes.\n\nDiabetes\n\n51\n\n:\n\n493\n\n–498,\n\n2002\n\n245.\n\nHaller MJ, Samyn M, Nichols WW, Brusko T, Wasserfall C, Schwartz RF, Atkinson M, Shuster JJ, Pierce GL, Silverstein JH: Radial artery tonometry demonstrates arterial stiffness in children with type 1 diabetes.\n\nDiabetes Care\n\n27\n\n:\n\n2911\n\n–2917,\n\n2004\n\n246.\n\nOrchard TJ, Forrest KY, Kuller LH, Becker DJ: Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study.\n\nDiabetes Care\n\n24\n\n:\n\n1053\n\n–1059,\n\n2001\n\n247.\n\nKavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, Parekh RS, Steinberger J: Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics.\n\nCirculation\n\n114\n\n:\n\n2710\n\n–2738,\n\n2006\n\n248.\n\nSalo P, Viikari J, Hamalainen M, Lapinleimu H, Routi T, Ronnemaa T, Seppanen R, Jokinen E, Valimaki I, Simell O: Serum cholesterol ester fatty acids in 7- and 13-month-old children in a prospective randomized trial of a low-saturated fat, low-cholesterol diet: the STRIP baby project. Special Turku coronary Risk factor Intervention Project for children.\n\nActa Paediatr\n\n88\n\n:\n\n505\n\n–512,\n\n1999\n\n249.\n\nEfficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol. The Dietary Intervention Study in Children (DISC). The Writing Group for the DISC Collaborative Research Group.\n\nJAMA\n\n273\n\n:\n\n1429\n\n–1435,\n\n1995\n\n250.\n\nMcCrindle BW, Ose L, Marais AD: Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial.\n\nJ Pediatr\n\n143\n\n:\n\n74\n\n–80,\n\n2003\n\n251.\n\nde Jongh S, Lilien MR, op't RJ, Stroes ES, Bakker HD, Kastelein JJ: Early statin therapy restores endothelial function in children with familial hypercholesterolemia.\n\nJ Am Coll Cardiol\n\n40\n\n:\n\n2117\n\n–2121,\n\n2002\n\n252.\n\nWiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Buller HR, Sijbrands EJ, Kastelein JJ: Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial.\n\nJAMA\n\n292\n\n:\n\n331\n\n–337,\n\n2004\n\n253.\n\nHolmes GK: Screening for coeliac disease in type 1 diabetes.\n\nArch Dis Child\n\n87\n\n:\n\n495\n\n–498,\n\n2002\n\n254.\n\nRewers M, Liu E, Simmons J, Redondo MJ, Hoffenberg EJ: Celiac disease associated with type 1 diabetes mellitus.\n\nEndocrinol Metab Clin North Am\n\n33\n\n:\n\n197\n\n–214, xi, 2004\n\n255.\n\nRoldan MB, Alonso M, Barrio R: Thyroid autoimmunity in children and adolescents with type 1 diabetes mellitus.\n\nDiabetes Nutr Metab\n\n12\n\n:\n\n27\n\n–31,\n\n1999\n\n256.\n\nKordonouri O, Deiss D, Danne T, Dorow A, Bassir C, Gruters-Kieslich A: Predictivity of thyroid autoantibodies for the development of thyroid disorders in children and adolescents with Type 1 diabetes.\n\nDiabet Med\n\n19\n\n:\n\n518\n\n–521,\n\n2002\n\n257.\n\nMohn A, Di Michele S, Di Luzio R, Tumini S, Chiarelli F: The effect of subclinical hypothyroidism on metabolic control in children and adolescents with type 1 diabetes mellitus.\n\nDiabet Med\n\n19\n\n:\n\n70\n\n–73,\n\n2002\n\n258.\n\nChase HP, Garg SK, Cockerham RS, Wilcox WD, Walravens PA: Thyroid hormone replacement and growth of children with subclinical hypothyroidism and diabetes.\n\nDiabet Med\n\n7\n\n:\n\n299\n\n–303,\n\n1990\n\n259.\n\nEppens MC, Craig ME, Cusumano J, Hing S, Chan AK, Howard NJ, Silink M, Donaghue KC: Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes.\n\nDiabetes Care\n\n29\n\n:\n\n1300\n\n–1306,\n\n2006\n\n260.\n\nKitzmiller JL, Gavin LA, Gin GD, Jovanovic-Peterson L, Main EK, Zigrang WD: Preconception care of diabetes. Glycemic control prevents congenital anomalies.\n\nJAMA\n\n265\n\n:\n\n731\n\n–736,\n\n1991\n\n261.\n\nGoldman JA, Dicker D, Feldberg D, Yeshaya A, Samuel N, Karp M: Pregnancy outcome in patients with insulin-dependent diabetes mellitus with preconceptional diabetic control: a comparative study.\n\nAm J Obstet Gynecol\n\n155\n\n:\n\n293\n\n–297,\n\n1986\n\n262.\n\nRosenn B, Miodovnik M, Combs CA, Khoury J, Siddiqi TA: Pre-conception management of insulin-dependent diabetes: improvement of pregnancy outcome.\n\nObstet Gynecol\n\n77\n\n:\n\n846\n\n–849,\n\n1991\n\n263.\n\nTchobroutsky C, Vray MM, Altman JJ: Risk/benefit ratio of changing late obstetrical strategies in the management of insulin-dependent diabetic pregnancies. A comparison between 1971–1977 and 1978–1985 periods in 389 pregnancies.\n\nDiabete Metab\n\n17\n\n:\n\n287\n\n–294,\n\n1991\n\n264.\n\nWillhoite MB, Bennert HW, Jr, Palomaki GE, Zaremba MM, Herman WH, Williams JR, Spear NH: The impact of preconception counseling on pregnancy outcomes: the experience of the Maine Diabetes in Pregnancy Program.\n\nDiabetes Care\n\n16\n\n:\n\n450\n\n–455,\n\n1993\n\n265.\n\nCooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA: Major congenital malformations after first-trimester exposure to ACE inhibitors.\n\nN Engl J Med\n\n354\n\n:\n\n2443\n\n–2451,\n\n2006\n\n266.\n\nKitzmiller JL, Buchanan TA, Kjos S, Combs CA, Ratner RE: Pre-conception care of diabetes, congenital malformations, and spontaneous abortions.\n\nDiabetes Care\n\n19\n\n:\n\n514\n\n–541,\n\n1996\n\n267.\n\nAmerican Diabetes Association: Preconception care of women with diabetes (Position Statement).\n\nDiabetes Care\n\n27(Suppl. 1)\n\n:\n\nS76\n\n–S78,\n\n2004\n\n268.\n\nBrown AF, Mangione CM, Saliba D, Sarkisian CA: Guidelines for improving the care of the older person with diabetes mellitus.\n\nJ Am Geriatr Soc\n\n51\n\n:\n\nS265\n\n–S280,\n\n2003\n\n269.\n\nCurb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.\n\nJAMA\n\n276\n\n:\n\n1886\n\n–1892,\n\n1996\n\n270.\n\nClement S, Braithwaite SS, Magee MF, Ahmann A, Smith EP, Schafer RG, Hirsh IB: Management of diabetes and hyperglycemia in hospitals.\n\nDiabetes Care\n\n27\n\n:\n\n553\n\n–591,\n\n2004\n\n271.\n\nAmerican Association of Clinical Endocrinologists: Inpatient diabetes and metabolic control: conference proceedings.\n\nEndocr Pract\n\n10(Suppl. 2)\n\n:\n\n1\n\n–108,\n\n2004\n\n272.\n\nGarber AJ, Moghissi ES, Bransome ED, Jr, Clark NG, Clement S, Cobin RH, Furnary AP, Hirsch IB, Levy P, Roberts R, van den BG, Zamudio V: American College of Endocrinology position statement on inpatient diabetes and metabolic control.\n\nEndocr Pract\n\n10(Suppl. 2)\n\n:\n\n4\n\n–9,\n\n2004\n\n273.\n\nACE/ADA Task Force on Inpatient Diabetes: American College of Endocrinology and American Diabetes Association consensus statement on inpatient diabetes and glycemic control: a call to action.\n\nDiabetes Care\n\n29\n\n:\n\n1955\n\n–1962,\n\n2006\n\n274.\n\nCenters for Disease Control and Prevention:\n\nHospitalizations for Diabetes as Any-Listed Diagnosis.\n\nAtlanta, GA, CDC,\n\n2003\n\n275.\n\nPomposelli JJ, Baxter JK, III, Babineau TJ, Pomfret EA, Driscoll DF, Forse RA, Bistrian BR: Early postoperative glucose control predicts nosocomial infection rate in diabetic patients.\n\nJ Parenter Enteral Nutr\n\n22\n\n:\n\n77\n\n–81,\n\n1998\n\n276.\n\nUmpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE: Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes.\n\nJ Clin Endocrinol Metab\n\n87\n\n:\n\n978\n\n–982,\n\n2002\n\n277.\n\nCapes SE, Hunt D, Malmberg K, Gerstein HC: Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview.\n\nLancet\n\n355\n\n:\n\n773\n\n–778,\n\n2000\n\n278.\n\nBolk J, van der PT, Cornel JH, Arnold AE, Sepers J, Umans VA: Impaired glucose metabolism predicts mortality after a myocardial infarction.\n\nInt J Cardiol\n\n79\n\n:\n\n207\n\n–214,\n\n2001\n\n279.\n\nMalmberg K: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group.\n\nBMJ\n\n314\n\n:\n\n1512\n\n–1515,\n\n1997\n\n280.\n\nMalmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year.\n\nJ Am Coll Cardiol\n\n26\n\n:\n\n57\n\n–65,\n\n1995\n\n281.\n\nMalmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, Hildebrandt P, MacLeod K, Laakso M, Torp-Pedersen C, Waldenstrom A: Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.\n\nEur Heart J\n\n26\n\n:\n\n650\n\n–661,\n\n2005\n\n282.\n\nMehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D, Paolasso E, Ahmed R, Xie C, Kazmi K, Tai J, Orlandini A, Pogue J, Liu L: Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial.\n\nJAMA\n\n293\n\n:\n\n437\n\n–446,\n\n2005\n\n283.\n\nCheung NW, Wong VW, McLean M: The hyperglycemia: intensive insulin infusion in infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction.\n\nDiabetes Care\n\n29\n\n:\n\n765\n\n–770,\n\n2006\n\n284.\n\nFurnary AP, Gao G, Grunkemeier GL, Wu Y, Zerr KJ, Bookin SO, Floten HS, Starr A: Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting.\n\nJ Thorac Cardiovasc Surg\n\n125\n\n:\n\n1007\n\n–1021,\n\n2003\n\n285.\n\nFurnary AP, Zerr KJ, Grunkemeier GL, Starr A: Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures.\n\nAnn Thorac Surg\n\n67\n\n:\n\n352\n\n–360,\n\n1999\n\n286.\n\nGolden SH, Peart-Vigilance C, Kao WH, Brancati FL: Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes.\n\nDiabetes Care\n\n22\n\n:\n\n1408\n\n–1414,\n\n1999\n\n287.\n\nZerr KJ, Furnary AP, Grunkemeier GL, Bookin S, Kanhere V, Starr A: Glucose control lowers the risk of wound infection in diabetics after open heart operations.\n\nAnn Thorac Surg\n\n63\n\n:\n\n356\n\n–361,\n\n1997\n\n288.\n\nvan den Bergh G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in the critically ill patients.\n\nN Engl J Med\n\n345\n\n:\n\n1359\n\n–1367,\n\n2001\n\n289.\n\nvan den Bergh G, Wouters PJ, Bouillon R, Weekers F, Verwaest C, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P: Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control.\n\nCrit Care Med\n\n31\n\n:\n\n359\n\n–366,\n\n2003\n\n290.\n\nvan den Bergh G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R: Intensive insulin therapy in the medical ICU.\n\nN Engl J Med\n\n354\n\n:\n\n449\n\n–461,\n\n2006\n\n291.\n\nPittas AG, Siegel RD, Lau J: Insulin Therapy for Critically Ill Hospitalized Patients: A Meta-analysis of Randomized Controlled Trials.\n\nArch Intern Med\n\n164\n\n:\n\n2005\n\n–2011,\n\n2004\n\n292.\n\nKrinsley J: Glycemic control in critically ill patients: Leuven and beyond.\n\nChest\n\n132\n\n:\n\n1\n\n–2,\n\n2007\n\n293.\n\nBrunkhorst FM, Reinhart K: Intensive insulin therapy in the ICU: benefit versus harm?\n\nIntensive Care Med\n\n33\n\n:\n\n1302\n\n,\n\n2007\n\n293a.\n\nGlucontrol Study. Available at www.glucontrol.org. Accessed 6 November\n\n2007\n\n.\n\n294.\n\nMiller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El Kebbi IM: Hypoglycemia in patients with type 2 diabetes mellitus.\n\nArch Intern Med\n\n161\n\n:\n\n1653\n\n–1659,\n\n2001\n\n295.\n\nMisbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA: Lactic acidosis in patients with diabetes treated with metformin.\n\nN Engl J Med\n\n338\n\n:\n\n265\n\n–266,\n\n1998\n\n296.\n\nMisbin RI: The phantom of lactic acidosis due to metformin in patients with diabetes.\n\nDiabetes Care\n\n27\n\n:\n\n1791\n\n–1793,\n\n2004\n\n297.\n\nSalpeter SR, Greyber E, Pasternak GA, Salpeter EE: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis.\n\nArch Intern Med\n\n163\n\n:\n\n2594\n\n–2602,\n\n2003\n\n298.\n\nQueale WS, Seidler AJ, Brancati FL: Glycemic control and sliding scale insulin use in medical inpatients with diabetes mellitus.\n\nArch Intern Med\n\n157\n\n:\n\n545\n\n–552,\n\n1997\n\n299.\n\nGearhart JG, Duncan JL, III, Replogle WH, Forbes RC, Walley EJ: Efficacy of sliding-scale insulin therapy: a comparison with prospective regimens.\n\nFam Pract Res J\n\n14\n\n:\n\n313\n\n–322,\n\n1994\n\n300.\n\nWalts LF, Miller J, Davidson MB, Brown J: Perioperative management of diabetes mellitus.\n\nAnesthesiology\n\n55\n\n:\n\n104\n\n–109,\n\n1981\n\n301.\n\nUmpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, Puig A, Mejia R: Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial).\n\nDiabetes Care\n\n30\n\n:\n\n2181\n\n–2186,\n\n2007\n\n302.\n\nSchmeltz LR, DeSantis AJ, Schmidt K, O'Shea-Mahler E, Rhee C, Brandt S, Peterson S, Molitch ME: Conversion of intravenous insulin infusions to subcutaneously administered insulin glargine in patients with hyperglycemia.\n\nEndocr Pract\n\n12\n\n:\n\n641\n\n–650,\n\n2006\n\n303.\n\nShilo S, Berezovsky S, Friedlander Y, Sonnenblick M: Hypoglycemia in hospitalized nondiabetic older patients.\n\nJ Am Geriatr Soc\n\n46\n\n:\n\n978\n\n–982,\n\n1998\n\n304.\n\nFischer KF, Lees JA, Newman JH: Hypoglycemia in hospitalized patients. Causes and outcomes.\n\nN Engl J Med\n\n315\n\n:\n\n1245\n\n–1250,\n\n1986\n\n305.\n\nMarkovitz LJ, Wiechmann RJ, Harris N, Hayden V, Cooper J, Johnson G, Harelstad R, Calkins L, Braithwaite SS: Description and evaluation of a glycemic management protocol for patients with diabetes undergoing heart surgery.\n\nEndocr Pract\n\n8\n\n:\n\n10\n\n–18,\n\n2002\n\n306.\n\nLevetan CS, Salas JR, Wilets IF, Zumoff B: Impact of endocrine and diabetes team consultation on hospital length of stay for patients with diabetes.\n\nAm J Med\n\n99\n\n:\n\n22\n\n–28,\n\n1995\n\n307.\n\nLevetan CS, Passaro MD, Jablonski KA, Ratner RE: Effect of physician specialty on outcomes in diabetic ketoacidosis.\n\nDiabetes Care\n\n22\n\n:\n\n1790\n\n–1795,\n\n1999\n\n308.\n\nKoproski J, Pretto Z, Poretsky L: Effects of an intervention by a diabetes team in hospitalized patients with diabetes.\n\nDiabetes Care\n\n20\n\n:\n\n1553\n\n–1555,\n\n1997\n\n309.\n\nFurnary AP, Braithwaite SS: Effects of outcome on in-hospital transition from intravenous insulin infusion to subcutaneous therapy.\n\nAm J Cardiol\n\n98\n\n:\n\n557\n\n–564,\n\n2006\n\n310.\n\nAmerican Diabetes Association: Diabetes nutrition recommendations for health care institutions (Position Statement).\n\nDiabetes Care\n\n27(Suppl. 1)\n\n:\n\nS55\n\n–S57,\n\n2004\n\n311.\n\nBoucher JL, Swift CS, Franz MJ, Kulkarni K, Schafer RG, Pritchett E, Clark NG: Inpatient management of diabetes and hyperglycemia: implications for nutrition practice and the food and nutrition professional.\n\nJ Am Diet Assoc\n\n107\n\n:\n\n105\n\n–111,\n\n2007\n\n312.\n\nDe Block C, Manuel YK, Van Gaal L, Rogiers P: Intensive insulin therapy in the intensive care unit: assessment by continuous glucose monitoring.\n\nDiabetes Care\n\n29\n\n:\n\n1750\n\n–1756,\n\n2006\n\n313.\n\nAmerican Diabetes Association: Diabetes care in the school and day care setting.\n\nDiabetes Care\n\n31(Suppl. 1)\n\n:\n\nS79\n\n–S86,\n\n2008\n\n314.\n\nNational Diabetes Education Program:\n\nHelping the Student with Diabetes Succeed: A Guide for School Personnel.\n\nAvailable at http://www.ndep.nih.gov/diabetes/youth/youth.htm. Accessed 6 November 2007\n\n315.\n\nAmerican Diabetes Association.\n\nDiabetes Care Tasks at School: What Key Personnel Need to Know.\n\nAvailable at http://www.diabetes.org/advocacy-and-legalresources/discrimination/school/schooltraining.jsp. Accessed 6 November 2007\n\n316.\n\nAmerican Diabetes Association: Diabetes care at diabetes camps.\n\nDiabetes Care\n\n29(Suppl. 1)\n\n:\n\nS56\n\n–S58,\n\n2006\n\n317.\n\nAmerican Diabetes Association: Diabetes management in correctional institutions.\n\nDiabetes Care\n\n31(Suppl. 1)\n\n:\n\nS87\n\n–S94,\n\n2008\n\n318.\n\nCefalu WT, Smith SR, Blonde L, Fonseca V: The Hurricane Katrina aftermath and its impact on diabetes care: observations from “ground zero”: lessons in disaster preparedness of people with diabetes.\n\nDiabetes Care\n\n29\n\n:\n\n158\n\n–160,\n\n2006\n\n319.\n\nAmerican Diabetes Association Statement on Emergency and Disaster Preparedness: a report of the Disaster Response Task Force.\n\nDiabetes Care\n\n30\n\n:\n\n2395\n\n–2398,\n\n2007\n\n320.\n\nAmerican Diabetes Association: Hypoglycemia and employment/licensure.\n\nDiabetes Care\n\n31(Suppl. 1)\n\n:\n\nS95\n\n,\n\n2008\n\n321.\n\nAmerican Diabetes Association: Third-party reimbursement for diabetes care, self-management education, and supplies.\n\nDiabetes Care\n\n31(Suppl. 1)\n\n:\n\nS96\n\n–S97,\n\n2008\n\n322.\n\nSaydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes.\n\nJAMA\n\n291\n\n:\n\n335\n\n–342,\n\n2004\n\n323.\n\nClark CM, Jr, Snyder JW, Meek RL, Stutz LM, Parkin CG: A systematic approach to risk stratification and intervention within a managed care environment improves diabetes outcomes and patient satisfaction.\n\nDiabetes Care\n\n24\n\n:\n\n1079\n\n–1086,\n\n2001\n\n324.\n\nMeigs JB, Cagliero E, Dubey A, Murphy-Sheehy P, Gildesgame C, Chueh H, Barry MJ, Singer DE, Nathan DM: A controlled trial of web-based diabetes disease management: the MGH diabetes primary care improvement project.\n\nDiabetes Care\n\n26\n\n:\n\n750\n\n–757,\n\n2003\n\n325.\n\nO'Connor PJ, Desai J, Solberg LI, Reger LA, Crain AL, Asche SE, Pearson TL, Clark CK, Rush WA, Cherney LM, Sperl-Hillen JM, Bishop DB: Randomized trial of quality improvement intervention to improve diabetes care in primary care settings.\n\nDiabetes Care\n\n28\n\n:\n\n1890\n\n–1897,\n\n2005\n\n326.\n\nSperl-Hillen JM, O'Connor PJ: Factors driving diabetes care improvement in a large medical group: ten years of progress.\n\nAm J Manag Care\n\n11\n\n:\n\nS177\n\n–S185,\n\n2005\n\n327.\n\nSiminerio LM: Implementing diabetes self-management training programs: breaking through the barriers in primary care.\n\nEndocr Pract\n\n12(Suppl. 1)\n\n:\n\n124\n\n–130,\n\n2006\n\n328.\n\nMahoney JJ: Reducing patient drug acquisition costs can lower diabetes health claims.\n\nAm J Manag Care\n\n11\n\n:\n\nS170\n\n–S176,\n\n2005\n\n329.\n\nManey M, Tseng CL, Safford MM, Miller DR, Pogach LM: Impact of self-reported patient characteristics upon assessment of glycemic control in the Veterans Health Administration.\n\nDiabetes Care\n\n30\n\n:\n\n245\n\n–251,\n\n2007\n\n330.\n\nBergenstal RM: Treatment models from the International Diabetes Center: advancing from oral agents to insulin therapy in type 2 diabetes.\n\nEndocr Pract\n\n12(Suppl. 1)\n\n:\n\n98\n\n–104,\n\n2006\n\n331.\n\nO'Connor PJ: Electronic medical records and diabetes care improvement: are we waiting for Godot?\n\nDiabetes Care\n\n26\n\n:\n\n942\n\n–943,\n\n2003\n\n332.\n\nShojania KG, Ranji SR, McDonald KM, Grimshaw JM, Sundaram V, Rushakoff RJ, Owens DK: Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis.\n\nJAMA\n\n296\n\n:\n\n427\n\n–440,\n\n2006"
    }
}